AR122341A1 - Método para el tratamiento de cáncer utilizando célula adyuvante artificial (aavc) - Google Patents
Método para el tratamiento de cáncer utilizando célula adyuvante artificial (aavc)Info
- Publication number
- AR122341A1 AR122341A1 ARP200103336A ARP200103336A AR122341A1 AR 122341 A1 AR122341 A1 AR 122341A1 AR P200103336 A ARP200103336 A AR P200103336A AR P200103336 A ARP200103336 A AR P200103336A AR 122341 A1 AR122341 A1 AR 122341A1
- Authority
- AR
- Argentina
- Prior art keywords
- cell
- person
- galcer
- cancer
- aavc
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 8
- 201000011510 cancer Diseases 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 5
- 239000002671 adjuvant Substances 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 18
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 abstract 7
- 230000002265 prevention Effects 0.000 abstract 5
- 230000037396 body weight Effects 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 238000012258 culturing Methods 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- User Interface Of Digital Computer (AREA)
Abstract
Se proporciona un método efectivo y seguro para tratar o prevenir un cáncer utilizando aAVC. La invención encuentra escala apropiadas de la dosis de a-GalCer cargado en la superficie de la célula aAVC, así como la cantidad de a-GalCer cargado en la superficie de la célula aAVC, en una composición farmacéutica que contiene aAVC, las cuales se prefieren en términos de garantizar la efectividad y seguridad en el tratamiento y prevención de un cáncer utilizando aAVC; y proporciona un método efectivo y seguro para el tratamiento o prevención de un cáncer utilizando aAVC para el tratamiento efectivo y seguro de un cáncer; y una composición farmacéutica que comprende a la misma, etc. Reivindicación 1: Un método para el tratamiento o prevención de un cáncer, comprendiendo la etapa de administrar una célula de origen humano a una persona; en el cual la célula expresa CD1d exógeno, tiene una a-galactosilceramida (a-GalCer) cargada en la superficie celular y en el cual se administra la célula a la persona de tal manera que la dosis única de a-GalCer cargada sobre dicha superficie celular varía desde 1,7 ng hasta 275 ng por kg de peso del cuerpo de la persona. Reivindicación 6: Una composición farmacéutica para el tratamiento o prevención de un cáncer, comprendiendo una célula de origen humano que expresa CD1d exógeno y tiene un a-GalCer cargado sobre la superficie celular; y se administra la composición a una persona de tal manera que una sola dosis de a-GalCer cargado en la superficie celular es de 1,7 ng hasta 275 ng por kg de peso del cuerpo de la persona. Reivindicación 16: Una célula de origen humano para ser utilizada en el tratamiento o prevención de un cáncer, la cual expresa CD1d exógeno y tiene un a-GalCer cargado sobre la superficie celular; y la cual se administra a una persona de tal manera que una sola dosis de a-GalCer cargado sobre la superficie de la célula varía desde 1,7 ng hasta 275 ng por kg de peso del cuerpo de la persona. Reivindicación 21: Un método para producir una célula de origen humano que expresa CD1d exógeno y tiene un a-GalCer cargado en la superficie celular, en el cual se administra la célula a una persona de tal manera que una sola dosis de a-GalCer cargado en la superficie de la célula varía desde 1,7 ng hasta 275 ng por kg de peso del cuerpo de la persona; y el método comprende la etapa de cultiva células de origen humano que expresan CD1d exógeno en un medio de cultivo que contiene 56 ng/mL hasta 3000 ng/mL de a-GalCer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019217712 | 2019-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122341A1 true AR122341A1 (es) | 2022-09-07 |
Family
ID=76222356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200103336A AR122341A1 (es) | 2019-12-02 | 2020-12-01 | Método para el tratamiento de cáncer utilizando célula adyuvante artificial (aavc) |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11617790B2 (es) |
| EP (1) | EP4070810A4 (es) |
| JP (2) | JP6912765B1 (es) |
| KR (1) | KR20220119029A (es) |
| CN (1) | CN114929272A (es) |
| AR (1) | AR122341A1 (es) |
| AU (1) | AU2020398783A1 (es) |
| BR (1) | BR112022010750A2 (es) |
| CA (1) | CA3162121A1 (es) |
| CL (1) | CL2022001458A1 (es) |
| CO (1) | CO2022008737A2 (es) |
| CR (1) | CR20220319A (es) |
| DO (1) | DOP2022000109A (es) |
| EC (1) | ECSP22049665A (es) |
| IL (1) | IL293483A (es) |
| JO (1) | JOP20220122A1 (es) |
| MX (1) | MX2022006712A (es) |
| PE (1) | PE20221421A1 (es) |
| TW (1) | TW202134265A (es) |
| WO (1) | WO2021112056A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1990410T (pt) * | 2006-02-22 | 2020-03-03 | Riken | Imunoterapia por utilização de uma célula capaz de co-expressar um antigénio alvo e cd1d e pulsada com um ligando de cd1d |
| US20130189302A1 (en) * | 2006-02-22 | 2013-07-25 | Riken | Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1990410T (pt) | 2006-02-22 | 2020-03-03 | Riken | Imunoterapia por utilização de uma célula capaz de co-expressar um antigénio alvo e cd1d e pulsada com um ligando de cd1d |
| US20130189302A1 (en) * | 2006-02-22 | 2013-07-25 | Riken | Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen |
| JP2007261876A (ja) | 2006-03-28 | 2007-10-11 | Tdk Corp | 誘電体粒子、誘電体磁器組成物およびその製造方法 |
| JPWO2010061930A1 (ja) | 2008-11-28 | 2012-04-26 | 独立行政法人理化学研究所 | ＣＤ１ｄ及び標的抗原の共発現アロ細胞を用いた免疫療法 |
| KR101194265B1 (ko) | 2008-12-01 | 2012-10-29 | 주식회사 한국인삼공사 | 해양심층수를 이용하여 인삼 또는 홍삼 농축액의 고미 제거방법 |
| WO2011119326A2 (en) | 2010-03-25 | 2011-09-29 | 3M Innovative Properties Company | Composite layer |
| US9783821B2 (en) | 2011-07-29 | 2017-10-10 | Riken | Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct |
| US10316332B2 (en) * | 2011-07-29 | 2019-06-11 | Riken | Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product |
-
2020
- 2020-12-01 AU AU2020398783A patent/AU2020398783A1/en active Pending
- 2020-12-01 MX MX2022006712A patent/MX2022006712A/es unknown
- 2020-12-01 IL IL293483A patent/IL293483A/en unknown
- 2020-12-01 JP JP2021513476A patent/JP6912765B1/ja active Active
- 2020-12-01 KR KR1020227020631A patent/KR20220119029A/ko active Search and Examination
- 2020-12-01 CR CR20220319A patent/CR20220319A/es unknown
- 2020-12-01 US US17/312,363 patent/US11617790B2/en active Active
- 2020-12-01 JO JOP/2022/0122A patent/JOP20220122A1/ar unknown
- 2020-12-01 EP EP20897410.5A patent/EP4070810A4/en active Pending
- 2020-12-01 WO PCT/JP2020/044587 patent/WO2021112056A1/ja active Application Filing
- 2020-12-01 CA CA3162121A patent/CA3162121A1/en active Pending
- 2020-12-01 PE PE2022000981A patent/PE20221421A1/es unknown
- 2020-12-01 AR ARP200103336A patent/AR122341A1/es unknown
- 2020-12-01 TW TW109142273A patent/TW202134265A/zh unknown
- 2020-12-01 CN CN202080083505.2A patent/CN114929272A/zh active Pending
- 2020-12-01 BR BR112022010750A patent/BR112022010750A2/pt unknown
-
2021
- 2021-06-29 JP JP2021108075A patent/JP2021155443A/ja active Pending
-
2022
- 2022-05-24 DO DO2022000109A patent/DOP2022000109A/es unknown
- 2022-06-02 CL CL2022001458A patent/CL2022001458A1/es unknown
- 2022-06-23 CO CONC2022/0008737A patent/CO2022008737A2/es unknown
- 2022-06-24 EC ECSENADI202249665A patent/ECSP22049665A/es unknown
-
2023
- 2023-03-06 US US18/179,289 patent/US20230381305A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220016239A1 (en) | 2022-01-20 |
| IL293483A (en) | 2022-08-01 |
| JP2021155443A (ja) | 2021-10-07 |
| MX2022006712A (es) | 2022-09-12 |
| EP4070810A1 (en) | 2022-10-12 |
| WO2021112056A1 (ja) | 2021-06-10 |
| TW202134265A (zh) | 2021-09-16 |
| KR20220119029A (ko) | 2022-08-26 |
| PE20221421A1 (es) | 2022-09-20 |
| CA3162121A1 (en) | 2021-06-10 |
| ECSP22049665A (es) | 2022-08-31 |
| JP6912765B1 (ja) | 2021-08-04 |
| BR112022010750A2 (pt) | 2022-08-16 |
| US11617790B2 (en) | 2023-04-04 |
| CN114929272A (zh) | 2022-08-19 |
| DOP2022000109A (es) | 2022-10-16 |
| CL2022001458A1 (es) | 2023-02-24 |
| EP4070810A4 (en) | 2024-04-17 |
| CR20220319A (es) | 2022-11-03 |
| US20230381305A1 (en) | 2023-11-30 |
| AU2020398783A1 (en) | 2022-06-09 |
| JPWO2021112056A1 (ja) | 2021-12-02 |
| CO2022008737A2 (es) | 2022-08-09 |
| JOP20220122A1 (ar) | 2023-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201200179A (es) | Métodos de tratamiento contra el cáncer pancreático | |
| CO7101246A2 (es) | Compuesto de carbamato y preparación y uso de los mismos | |
| CO6311006A2 (es) | Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas | |
| AR122341A1 (es) | Método para el tratamiento de cáncer utilizando célula adyuvante artificial (aavc) | |
| AR105712A1 (es) | Composiciones de insulina de rápida acción | |
| AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| BR112018069251A2 (pt) | métodos de intervenção precoce para prevenir ou melhorar a toxicidade | |
| AR084938A1 (es) | Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes | |
| PE20080765A1 (es) | Formas de dosificacion farmaceutica | |
| AR049985A1 (es) | Tratamiento de combinacion para enfermedades malignas no hematologicas | |
| PE20081311A1 (es) | Metodos que usan 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidin-2,6-diona para el tratamiento de linfomas de las celulas del manto | |
| CO6311007A2 (es) | Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+, efectiva a dosis bajas | |
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| AR078224A1 (es) | Composicon para el tratamiento del cancer de prostata | |
| ES2570401T3 (es) | Métodos de tratamiento usando dosis únicas de oritavancina | |
| BR112016007100A2 (pt) | tratamento contra tumor combinado usando interferon gama e minicélulas carregadas com fármaco dirigidas a ligantes biespecíficos | |
| AR112166A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de hepatitis b | |
| BR112013027010A2 (pt) | método de produzir substâncias com gás supersaturado, dispositivo para sua entrega trasdérmica, e seus usos | |
| BR112022000382A2 (pt) | Administração de agonista de sting e inibidores de checkpoint | |
| ECSP20000655A (es) | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO | |
| WO2019098759A3 (ko) | 형질전환된 인간세포 및 이의 용도 | |
| AR053799A1 (es) | Composiciones que contienen policonasol y teaflavina y sus usos farmaceuticos | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| RU2442601C2 (ru) | Средство, усиливающее мобилизацию стволовых клеток | |
| Silva et al. | Comparative analysis of different doses of coherent light (laser) and non-coherent light (light-emitting diode) on cellular necrosis and apoptosis: a study in vitro |